2024 Q2 Form 10-Q Financial Statement
#000157628024000109 Filed on May 09, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| Revenue | $177.2M | $168.5M |
| YoY Change | 29.23% | 30.9% |
| Cost Of Revenue | $72.42M | $65.30M |
| YoY Change | 34.49% | 23.03% |
| Gross Profit | $104.8M | $103.2M |
| YoY Change | 25.82% | 36.43% |
| Gross Profit Margin | 59.14% | 61.25% |
| Selling, General & Admin | $122.3M | $119.1M |
| YoY Change | 8.68% | 2.15% |
| % of Gross Profit | 116.71% | 115.39% |
| Research & Development | $83.10M | $83.80M |
| YoY Change | -8.03% | -10.01% |
| % of Gross Profit | 79.29% | 81.21% |
| Depreciation & Amortization | $10.10M | $10.71M |
| YoY Change | -4.99% | 3.55% |
| % of Gross Profit | 9.64% | 10.38% |
| Operating Expenses | $205.4M | $202.9M |
| YoY Change | 1.24% | -3.25% |
| Operating Profit | -$100.6M | -$99.68M |
| YoY Change | -15.88% | -25.64% |
| Interest Expense | $28.77M | $645.0K |
| YoY Change | -58.95% | 0.16% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$15.15M | -$29.12M |
| YoY Change | -1863.1% | 1660.58% |
| Pretax Income | -$102.5M | -$114.6M |
| YoY Change | 41.81% | -14.04% |
| Income Tax | $133.0K | $405.0K |
| % Of Pretax Income | ||
| Net Earnings | -$102.6M | -$115.0M |
| YoY Change | 41.03% | -13.89% |
| Net Earnings / Revenue | -57.91% | -68.24% |
| Basic Earnings Per Share | -$0.84 | -$0.94 |
| Diluted Earnings Per Share | -$0.84 | -$0.94 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 122.4M shares | 121.7M shares |
| Diluted Shares Outstanding | 122.4M shares | 121.7M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $933.7M | $1.029B |
| YoY Change | -23.77% | 9.82% |
| Cash & Equivalents | $933.7M | $1.029B |
| Short-Term Investments | $0.00 | $0.00 |
| Other Short-Term Assets | $188.8M | $31.74M |
| YoY Change | 631.44% | -6.0% |
| Inventory | $66.98M | $62.99M |
| Prepaid Expenses | ||
| Receivables | $100.5M | $84.56M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $1.290B | $1.309B |
| YoY Change | -7.7% | 18.48% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $132.3M | $138.4M |
| YoY Change | -58.78% | -15.22% |
| Goodwill | $3.290M | $3.290M |
| YoY Change | 0.0% | 0.0% |
| Intangibles | $7.742M | $8.294M |
| YoY Change | -25.28% | -24.92% |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $29.91M | $94.20M |
| YoY Change | -72.23% | 59.79% |
| Total Long-Term Assets | $319.4M | $396.1M |
| YoY Change | -27.8% | -2.73% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $1.290B | $1.309B |
| Total Long-Term Assets | $319.4M | $396.1M |
| Total Assets | $1.609B | $1.705B |
| YoY Change | -12.54% | 12.77% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $42.45M | $37.60M |
| YoY Change | -46.8% | -44.14% |
| Accrued Expenses | $70.68M | $67.21M |
| YoY Change | -35.1% | -64.72% |
| Deferred Revenue | $29.38M | $22.56M |
| YoY Change | 140.05% | 65.6% |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $201.6M | $220.0M |
| YoY Change | 0.32% | 7.77% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $1.141B | $1.141B |
| YoY Change | 0.23% | 0.23% |
| Other Long-Term Liabilities | $95.93M | $96.79M |
| YoY Change | -53.81% | 959.39% |
| Total Long-Term Liabilities | $95.93M | $96.79M |
| YoY Change | -92.87% | 959.39% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $201.6M | $220.0M |
| Total Long-Term Liabilities | $95.93M | $96.79M |
| Total Liabilities | $1.611B | $1.636B |
| YoY Change | 4.11% | 5.15% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$2.359B | -$2.257B |
| YoY Change | 26.26% | 25.66% |
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$1.613M | $68.29M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $1.609B | $1.705B |
| YoY Change | -12.54% | 12.77% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$102.6M | -$115.0M |
| YoY Change | 41.03% | -13.89% |
| Depreciation, Depletion And Amortization | $10.10M | $10.71M |
| YoY Change | -4.99% | 3.55% |
| Cash From Operating Activities | -$94.00M | -$30.28M |
| YoY Change | -0.01% | -59.32% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $5.077M | $6.934M |
| YoY Change | -22.05% | -7.84% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | $35.00M |
| YoY Change | -100.0% | -78.76% |
| Cash From Investing Activities | -$5.077M | $28.07M |
| YoY Change | -97.89% | -82.15% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 5.898M | -$1.074M |
| YoY Change | -98.46% | 25.76% |
| NET CHANGE | ||
| Cash From Operating Activities | -94.00M | -$30.28M |
| Cash From Investing Activities | -5.077M | $28.07M |
| Cash From Financing Activities | 5.898M | -$1.074M |
| Net Change In Cash | -93.18M | -$4.430M |
| YoY Change | -291.29% | -105.42% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$94.00M | -$30.28M |
| Capital Expenditures | $5.077M | $6.934M |
| Free Cash Flow | -$99.08M | -$37.22M |
| YoY Change | -1.44% | -54.59% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | gh |
Revenue From Development Services
RevenueFromDevelopmentServices
|
12262000 | usd |
| CY2023Q1 | gh |
Revenue From Development Services
RevenueFromDevelopmentServices
|
15321000 | usd |
| CY2024Q1 | us-gaap |
Revenues
Revenues
|
168491000 | usd |
| CY2023Q1 | us-gaap |
Revenues
Revenues
|
128714000 | usd |
| CY2024Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
268174000 | usd |
| CY2023Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
262769000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-99683000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-134055000 | usd |
| CY2024Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
14868000 | usd |
| CY2023Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3060000 | usd |
| CY2024Q1 | gh |
Costs Of Precision Oncology Testing
CostsOfPrecisionOncologyTesting
|
59306000 | usd |
| CY2023Q1 | gh |
Costs Of Precision Oncology Testing
CostsOfPrecisionOncologyTesting
|
45106000 | usd |
| CY2024Q1 | gh |
Cost Of Development Services
CostOfDevelopmentServices
|
5990000 | usd |
| CY2023Q1 | gh |
Cost Of Development Services
CostOfDevelopmentServices
|
7967000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
83802000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
93128000 | usd |
| CY2024Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
80425000 | usd |
| CY2023Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
76123000 | usd |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
38651000 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
40445000 | usd |
| CY2024Q1 | us-gaap |
Interest Expense
InterestExpense
|
645000 | usd |
| CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
644000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-29120000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1654000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-114580000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-133293000 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
405000 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
240000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-114985000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-133533000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.94 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.94 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.30 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.30 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
121712000 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
121712000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
102663000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
102663000 | shares |
| CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-114985000 | usd |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-133533000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
14000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
7535000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
|
-1138000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
|
-163000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-1124000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
7372000 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-116109000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-126161000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
158684000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
213000 | usd |
| CY2024Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
1544000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
27041000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-1124000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-114985000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
68285000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
60180000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
157000 | usd |
| CY2023Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
993000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
22266000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
7372000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-133533000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-44551000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-114985000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-133533000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
10712000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
10345000 | usd |
| CY2024Q1 | gh |
Non Cash Operating Lease Costs
NonCashOperatingLeaseCosts
|
7619000 | usd |
| CY2023Q1 | gh |
Non Cash Operating Lease Costs
NonCashOperatingLeaseCosts
|
7339000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
27041000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
22266000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
645000 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
644000 | usd |
| CY2024Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-111000 | usd |
| CY2023Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
1009000 | usd |
| CY2024Q1 | us-gaap |
Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
|
-30054000 | usd |
| CY2023Q1 | us-gaap |
Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
|
3882000 | usd |
| CY2024Q1 | us-gaap |
Other Asset Impairment Charges
OtherAssetImpairmentCharges
|
0 | usd |
| CY2023Q1 | us-gaap |
Other Asset Impairment Charges
OtherAssetImpairmentCharges
|
5485000 | usd |
| CY2024Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-652000 | usd |
| CY2023Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
300000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-4220000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-12349000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1042000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-5125000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
5627000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
3354000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-1024000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-1765000 | usd |
| CY2024Q1 | gh |
Increase Decrease In Accounts Payable Accrued And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities
|
13240000 | usd |
| CY2023Q1 | gh |
Increase Decrease In Accounts Payable Accrued And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities
|
13886000 | usd |
| CY2024Q1 | gh |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-8835000 | usd |
| CY2023Q1 | gh |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-7422000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
4887000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-4145000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-30284000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-74441000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
63252000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
35000000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
228000000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
6934000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
7524000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
28066000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
157224000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
213000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
157000 | usd |
| CY2024Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
1544000 | usd |
| CY2023Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
993000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
257000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-18000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1074000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-854000 | usd |
| CY2024Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-1138000 | usd |
| CY2023Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-163000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-4430000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
81766000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1133687000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
141948000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1129257000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
223714000 | usd |
| CY2024Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
1640000 | usd |
| CY2023Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
8016000 | usd |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1029027000 | usd |
| CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
223640000 | usd |
| CY2024Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
100230000 | usd |
| CY2023Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
74000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1129257000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
223714000 | usd |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non-marketable securities, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. | |
| CY2024Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
100200000 | usd |
| CY2024Q1 | us-gaap |
Equity Securities Fv Ni
EquitySecuritiesFvNi
|
8600000 | usd |
| CY2023Q4 | us-gaap |
Equity Securities Fv Ni
EquitySecuritiesFvNi
|
8600000 | usd |
| CY2023 | gh |
Equity Security Fvni Impairment Of Purchase Rights
EquitySecurityFVNIImpairmentOfPurchaseRights
|
22100000 | usd |
| CY2023Q1 | gh |
Equity Security Fvni Impairment Of Purchase Rights
EquitySecurityFVNIImpairmentOfPurchaseRights
|
5500000 | usd |
| CY2022 | gh |
Equity Security Fvni Impairment Of Purchase Rights
EquitySecurityFVNIImpairmentOfPurchaseRights
|
5300000 | usd |
| CY2023Q2 | gh |
Equity Security Fvni Impairment Of Purchase Rights
EquitySecurityFVNIImpairmentOfPurchaseRights
|
7000000 | usd |
| CY2024Q1 | gh |
Equity Security Fvni Impairment Or Adjustments To Carrying Value
EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue
|
0 | usd |
| CY2024Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable debt securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any.</span></div> | |
| CY2024Q1 | us-gaap |
Contract With Customer Asset Net
ContractWithCustomerAssetNet
|
4300000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Asset Net
ContractWithCustomerAssetNet
|
4900000 | usd |
| CY2024Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
| CY2024Q1 | us-gaap |
Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
|
0 | usd |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
35525000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
67211000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
63475000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
27800000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
22900000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
5300000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
5000000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
7100000 | usd |
| CY2023Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
6400000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
275523000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
272404000 | usd |
| CY2024Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
137136000 | usd |
| CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
127308000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
138387000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
145096000 | usd |
| CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
10000000 | usd |
| CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
9600000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
27957000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
27950000 | usd |
| CY2024Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
39254000 | usd |
| CY2024Q1 | gh |
Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost
DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost
|
1067288000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
2000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
0 | usd |
| CY2024Q1 | gh |
Cash Cash Equivalents And Debt Securities Fair Value
CashCashEquivalentsAndDebtSecuritiesFairValue
|
1067290000 | usd |
| CY2023Q4 | gh |
Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost
DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost
|
1067608000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
11000 | usd |
| CY2023Q4 | gh |
Cash Cash Equivalents And Debt Securities Fair Value
CashCashEquivalentsAndDebtSecuritiesFairValue
|
1067597000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
|
0 | usd |
| CY2023Q1 | us-gaap |
Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
|
0 | usd |
| CY2023Q1 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
|
0 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
|
0 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
18586000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
10292000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
8294000 | usd |
| CY2024Q1 | us-gaap |
Goodwill
Goodwill
|
3290000 | usd |
| CY2024Q1 | us-gaap |
Goodwill
Goodwill
|
3290000 | usd |
| CY2024Q1 | gh |
Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
|
21876000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
10292000 | usd |
| CY2024Q1 | us-gaap |
Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
|
11584000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
18586000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
9607000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
8979000 | usd |
| CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
3290000 | usd |
| CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
3290000 | usd |
| CY2023Q4 | gh |
Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
|
21876000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
9607000 | usd |
| CY2023Q4 | us-gaap |
Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
|
12269000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
700000 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
700000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
1534000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
1670000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
1212000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
1107000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
1109000 | usd |
| CY2024Q1 | gh |
Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
|
1662000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
8294000 | usd |
| CY2020Q4 | gh |
Convertible Debt Hedge Strike Price
ConvertibleDebtHedgeStrikePrice
|
182.60 | |
| CY2020Q4 | gh |
Convertible Debt Hedge Share Price Premium Percentage
ConvertibleDebtHedgeSharePricePremiumPercentage
|
0.75 | |
| CY2020Q4 | us-gaap |
Share Price
SharePrice
|
104.34 | |
| CY2020Q4 | gh |
Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Hedges
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges
|
90000000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
7600000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
7300000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P8Y1M6D | |
| CY2023Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P8Y3M18D | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0382 | |
| CY2023Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0387 | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
26576000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
33193000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
28146000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
24479000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
23321000 | usd |
| CY2024Q1 | gh |
Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
|
101835000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4159678 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
31.32 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y6M | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
237550000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
30686000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
206864000 | usd |
| CY2023 | us-gaap |
Dividends Common Stock
DividendsCommonStock
|
0 | usd |
| CY2024Q1 | us-gaap |
Dividends Common Stock
DividendsCommonStock
|
0 | usd |
| CY2024Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
29354235 | shares |
| CY2023Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
24715971 | shares |
| CY2023Q2 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
14375000 | shares |
| CY2023Q2 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
28.00 | |
| CY2023Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
381400000 | usd |
| CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
21100000 | usd |
| CY2023Q4 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
3387446 | shares |
| CY2023Q4 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
26.77 | |
| CY2023Q4 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
90600000 | usd |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
12003394 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4012903 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
31.76 | |
| CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y7M6D | |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
39115000 | usd |
| CY2024Q1 | gh |
Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
|
3689000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
216232 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
20.14 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
36791 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
5.78 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
32666 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
40.29 | |
| CY2024Q1 | gh |
Share Based Compensation Arrangement By Share Based Payment Award Adjustments In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardAdjustmentsInPeriodGross
|
48234 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
15841946 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
27035000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
2454606 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
26.85 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P4Y9M18D | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
26383000 | usd |
| CY2024Q1 | gh |
Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
|
3689000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
12.92 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
19.82 | |
| CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
37000000 | usd |
| CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y3M18D | |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
27041000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
22266000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
0 | shares |
| CY2023Q1 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
0 | shares |
| CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-114985000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-114985000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-133533000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-133533000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.94 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.94 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.30 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.30 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
121712000 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
121712000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
102663000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
102663000 | shares |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
19580000 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
18015000 | shares |
| CY2024Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
| CY2024Q1 | us-gaap |
Revenues
Revenues
|
168491000 | usd |
| CY2023Q1 | us-gaap |
Revenues
Revenues
|
128714000 | usd |
